Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Net Cash Flow (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of Net Cash Flow data on record, last reported at -$18.2 million in Q3 2025.

  • For Q3 2025, Net Cash Flow rose 58.23% year-over-year to -$18.2 million; the TTM value through Sep 2025 reached -$66.5 million, down 66.34%, while the annual FY2024 figure was -$63.2 million, 181.19% down from the prior year.
  • Net Cash Flow reached -$18.2 million in Q3 2025 per STOK's latest filing, up from -$173.3 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $146.8 million in Q1 2025 and bottomed at -$173.3 million in Q2 2025.
  • Average Net Cash Flow over 4 years is -$4.1 million, with a median of -$2.1 million recorded in 2023.
  • Peak YoY movement for Net Cash Flow: crashed 1986.41% in 2024, then surged 1241.69% in 2025.
  • A 4-year view of Net Cash Flow shows it stood at $160000.0 in 2022, then soared by 815.62% to $1.5 million in 2023, then plummeted by 1588.46% to -$21.8 million in 2024, then grew by 16.76% to -$18.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were -$18.2 million in Q3 2025, -$173.3 million in Q2 2025, and $146.8 million in Q1 2025.